Abstract: The present application provides an orthopedic implant or a part thereof, comprising biodegradable magnesium alloy comprising magnesium and Ca in the range of 0.550-0.700 wt %, Zn in the range of 0.400-0.700 wt %, and Fe 50 ppm or less, the biodegradable magnesium alloy consisting of two phases comprising a first phase comprising magnesium and Zn and a second phase less noble than the first phase, the second phase comprising Mg2Ca precipitates larger than nano-sized. The present application also provides a method for preparing the biodegradable magnesium alloy, a method for preparing the orthopedic implant or the part thereof, and a method for treating a subject in need of therapy for a medical condition of a bone.

Abstract: The present application provides an implant comprising magnesium alloy comprising Ca in the range of 0.3-2 wt %, Zn in the range of 0.5-6 wt %, Fe in the range of 50-100 ppm, and Zr in the range of 100-900 ppm and total impurities including Fe and Zr in the range of 400-1000 ppm. The present application also provides a method for preparing an implant, the method comprising providing biodegradable magnesium alloy having an average grain size of 40 ?m or less and comprising Ca in the range of 0.3-2 wt %, Zn in the range of 0.5-6 wt %, Fe in the range of 50-100 ppm, and Zr in the range of 100-900 ppm and total impurities including Fe and Zr in the range of 400-1000 ppm, and forming the biodegradable magnesium alloy into the implant.

Abstract: The present invention provides an orthopedic implant comprising a continuous reinforced composite filament in a freely predetermined fiber orientation in multiple continuous successive layers, wherein the continuous reinforced composite filament comprises a bioabsorbable polymer matrix and a continuous bioabsorbable reinforcing fiber or fiber bundle, and whereby the continuous bioabsorbable reinforcing fiber or fiber bundle of consecutive layers at least partly intermingles and/or intertwines forming a three dimensionally interlocked continuous fiber structure.

Abstract: The invention relates to a biodegradable, bioactive and bio-compatible glass composition comprising: SiO2 65-75 wt-%, Na2O 12-17 wt-%, CaO 8-11 wt-%, MgO 3-7 wt-%, P2O5 0.5-2.5 wt-%, B2O3 1-4 wt-%, K2O>0.5 wt-%-4 wt-%, SrO 0-4 wt-%, and at most 0.3 wt-% in total of Al2O3 and Fe2O3. The invention also relates to glass fiber comprising the glass composition and use of the glass fiber in medical and nonmedical applications.

Abstract: The present disclosure relates to a composite material comprising glass fiber and a polymer blend comprising polylactic acid (PLA) and polybutylene succinate (PBS), wherein the composite material comprises about 10 wt-% to about 80 wt-% of glass fibre, and wherein the polymer blend comprises about 20 wt-% to about 60 wt-% of PLA and about 40 wt-% to about 80 wt-% of PBS. The disclosure also relates to an article comprising the reinforced composite material.

Abstract: The present invention provides an orthopedic implant comprising a continuous reinforced composite filament in a freely predetermined fiber orientation in multiple continuous successive layers, wherein the continuous reinforced composite filament comprises a bioabsorbable polymer matrix and a continuous bioabsorbable reinforcing fiber or fiber bundle, and whereby the continuous bioabsorbable reinforcing fiber or fiber bundle of consecutive layers at least partly intermingles and/or intertwines forming a three dimensionally interlocked continuous fiber structure.

Abstract: Biocompatible and resorbable melt derived glass compositions which include: SiO2 60-70 weight-%, Na2O 5-20 weight-%, CaO 5-25 weight-%, MgO 0-10 weight-%, P2O5 0.5-3.0 weight-%, B2O3 0-15 weight-%, Al2O3 0-5 weight-%, and which contain less than 0.05 weight-% potassium. Biocompatible and resorbable glass fibers manufactured from these glass compositions, medical devices containing fibers of the invention, the use of these compositions for the manufacture of glass fiber and the use of the fibers for the manufacture of medical devices are also disclosed.

Abstract: A composite material including biocompatible and bioresorbable glass, a biocompatible and bioresorbable matrix polymer and a coupling agent capable of forming covalent bonds. The composite also includes a compatibilizer, where at least 10% of the structural units of the compatibilizer are identical to the structural units of the matrix polymer, and the molecular weight of the compatibilizer is less than 30000 g/mol. The use of this composite, a medical device which includes the composite and a method for preparing the composite are also disclosed.

Abstract: The present invention relates to an implantable paste comprising bioactive glass spheres having a size distribution of 50-425 ?m, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight polyethylene glycol having a molecular weight range of 700-2500 g/mol and high molecular weight polyethylene glycol having a molecular weight range of 2500-8000 g/mol, with the proviso that the molecular weight of the low molecular weight polyethylene glycol and of the medium molecular weight polyethylene glycol differ from each other by at least 80 g/mol and that the molecular weight of the medium molecular weight polyethylene glycol and of the high molecular weight polyethylene glycol differ from each other by at least 300 g/mol.

Abstract: Biocompatible and resorbable melt derived glass compositions which include: SiO2 60-70 weight-%, Na2O 5-20 weight-%, CaO 5-25 weight-%, MgO 0-10 weight-%, P2O5 0.5-3.0 weight-%, B2O3 0-15 weight-%, Al2O3 0-5 weight-%, and which contain less than 0.05 weight-% potassium. Biocompatible and resorbable glass fibres manufactured from these glass compositions, medical devices containing fibres of the invention, the use of these compositions for the manufacture of glass fibre and the use of the fibres for the manufacture of medical devices are also disclosed.

Abstract: The present invention relates to an implantable paste comprising bioactive glass spheres having a size distribution of 50-425 ?m, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight polyethylene glycol having a molecular weight range of 700-2500 g/mol and high molecular weight polyethylene glycol having a molecular weight range of 2500-8000 g/mol, with the proviso that the molecular weight of the low molecular weight polyethylene glycol and of the medium molecular weight polyethylene glycol differ from each other by at least 80 g/mol and that the molecular weight of the medium molecular weight polyethylene glycol and of the high molecular weight polyethylene glycol differ from each other by at least 300 g/mol.

Abstract: Biocompatible and resorbable melt derived glass compositions which include: SiO2 60-70 weight-%, Na2O 5-20 weight-%, CaO 5-25 weight-%, MgO 0-10 weight-%, P2O5 0.5-3.0 weight-%, B2O3 0-15 weight-%, Al2O3 0-5 weight-%, and which contain less than 0.05 weight-% potassium. Biocompatible and resorbable glass fibres manufactured from these glass compositions, medical devices containing fibres of the invention, the use of these compositions for the manufacture of glass fibre and the use of the fibres for the manufacture of medical devices are also disclosed.

Abstract: A composite material including biocompatible and bioresorbable glass, a biocompatible and bioresorbable matrix polymer and a coupling agent capable of forming covalent bonds. The composite also includes a compatibilizer, where at least 10% of the structural units of the compatibilizer are identical to the structural units of the matrix polymer, and the molecular weight of the compatibilizer is less than 30000 g/mol. The use of this composite, a medical device which includes the composite and a method for preparing the composite are also disclosed.

Abstract: Modifications of an inhaler and method of use thereof are described. In some embodiments, an inhaler may include one or more systems and/or methods that function to inhibit a child from accessing medicant from an inhaler. A system may function to inhibit a child from accessing an opening of an inhaler from which medicants are dispensed. In some embodiments, a system may inhibit a child from removing a cap for an inhaler. A system may function to inhibit a child from actuating an activation mechanism for an inhaler. A system may function to inhibit a user and/or a child from accidentally actuating an activation mechanism for an inhaler multiple times possibly resulting in an overdose. A system may function to inhibit an activation mechanism for an inhaler from actuating after the activation mechanism has been actuated a predetermined number of times. An inhaler may include a security fitting which functions to permanently plug an inhaler once a prescribed user is finished with the inhaler.

Abstract: A reserve power system includes a reserve power machine (2) for the generation of power. The reserve power machine (2) is connected via a distribution network (4) to consumers (10,12) and elevator drives (8). The elevator drives include an elevator hoisting motor (28) and a frequency converter (26) controlling it. The elevator drives are provided with regulating devices (26, 44, 46) by means of which the speed of the elevator motor (28) is so adjusted that the power taken by the elevator drive (8) from the distribution network (4) is lower than an adjustable power limit (P.sub.A).

Abstract: A velocity-controlled elevator drive including an a.c. motor (28) driving elevator machinery regulated by means of a frequency converter (26) supplying the motor (28) with a controlled frequency and voltage. The load condition of the elevator is measured by means of a load weighing device (32) in the elevator car. A power limit (P.sub.A) is input to the elevator machinery as a reference value and the speed reference (38) given to the frequency converter is determined on the basis of the power limit (P.sub.A) and the load condition.